|Gebot||77,02 x 50000|
|Briefkurs||77,08 x 50000|
|Tagesspanne||76,38 - 76,54|
|52-Wochen-Spanne||52,23 - 84,73|
|Beta (5 J., monatlich)||0,43|
|Kurs-Gewinn-Verhältnis (roll. Hochrechn.)||31,63|
|EPS (roll. Hochrechn.)||2,42|
|Gewinndatum||02. Feb. 2023|
|Erwartete Dividende & Rendite||2,75 (3,58%)|
|Ex-Dividendendatum||14. Dez. 2022|
NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. "We relied on traditional Latino ...
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...
In the spring of 2018, North Carolina native Stephanie Walker went to her first breast cancer conference and had a revelation that she refers to as her "coming-out party." She learned she had metastatic breast cancer three years earlier and although she was a retired hospice nurse, she faced the disease without any guidance from others who shared her experience.